Cortagen
A short synthetic tetrapeptide bioregulator (Ala-Glu-Asp-Pro) developed by the Khavinson Institute in Russia. Designed to normalize brain cortex function by modulating gene expression in cortical neurons. Part of the Khavinson peptide bioregulator family alongside Epithalon and Vilon. One of the few peptides specifically formulated for cortical brain function optimization, available in both injectable and oral/sublingual forms.
Typical Dosage
Oral/sublingual: 10-20 mg once daily. Injectable: 1-10 mg subcutaneous once daily. Typical course: 10-20 days, repeated two or three times yearly. Available in capsule form in some markets.
Administration
Oral, sublingual, or subcutaneous injection
Mechanism of Action
Cortagen (Ala-Glu-Asp-Pro) is a synthetic tetrapeptide belonging to the Khavinson family of peptide bioregulators — short peptides proposed to regulate gene expression in a tissue-specific manner. The bioregulator hypothesis, developed by Professor Vladimir Khavinson over decades of research at the St. Petersburg Institute of Bioregulation and Gerontology, proposes that short peptides (2-4 amino acids) can penetrate cell membranes and nuclear envelopes, interact directly with DNA in a sequence-specific manner, and modulate transcription of tissue-relevant genes.
Cortagen is specifically designed to target neurons of the cerebral cortex. According to the Khavinson model, the AEDP tetrapeptide sequence has complementarity to specific DNA sequences in gene promoter regions active in cortical neurons. Upon binding to these regulatory elements, Cortagen is proposed to modulate chromatin structure and transcription factor access, influencing the expression of genes involved in neuronal function, synaptic transmission, antioxidant defense, and protein synthesis. The tissue specificity — cortex rather than other brain regions or body tissues — is attributed to the unique chromatin accessibility and transcription factor environment in cortical neurons that determines which genes are available for regulation.
Preclinical studies from Russian research programs have reported that Cortagen treatment improves cognitive function, enhances learning and memory, and provides neuroprotection in models of cerebral ischemia and age-related cognitive decline. The proposed mechanism involves restoration of age-related declines in protein synthesis in cortical neurons, enhancement of antioxidant enzyme expression (SOD, catalase, GPx), and improved synaptic function through upregulation of synaptophysin and other synaptic proteins. It should be noted that the peptide bioregulator field remains controversial in Western pharmacology — while the Russian research program is extensive, the proposed direct DNA-binding mechanism has not been independently validated through the standard molecular biology methods expected in Western peer-reviewed literature.
Regulatory Status
Approved in Russia as a peptide bioregulator. Not FDA approved. Available through specialized suppliers. Limited peer-reviewed Western research.
Risks & Safety
Common: mild headache, transient fatigue during initial course. Serious: limited Western safety data — most evidence comes from Russian-language literature, unknown long-term effects of repeated cortical gene modulation. Rare: allergic reactions. Generally reported as well tolerated in Russian clinical use. Not FDA approved.
Research Papers
No research papers indexed yet. Papers are fetched from PubMed weekly.
Related Peptides
AEDG Peptide
A tetrapeptide (Ala-Glu-Asp-Gly) identical to Epithalon's core active sequence — effectively the same compound. Studied for telomerase activation and pineal gland regulation, promoting melatonin production and potentially slowing cellular aging through telomere maintenance. Part of the Khavinson bioregulator peptide family developed at the Institute of Bioregulation and Gerontology in St. Petersburg.
Cerebrolysin
A porcine brain-derived peptide preparation containing a standardized mixture of low-molecular-weight neuropeptides and free amino acids. One of the most widely used neurotrophic treatments globally, approved in over 40 countries for stroke recovery, traumatic brain injury, and neurodegenerative diseases. Mimics the action of endogenous neurotrophic factors (BDNF, NGF, CNTF) to promote neuronal survival, synaptic plasticity, and neurogenesis.
CJC-1295 (no DAC)
A synthetic GHRH analogue (also called Mod GRF 1-29) consisting of the first 29 amino acids of native GHRH with four amino acid substitutions for increased enzymatic stability. Stimulates natural, pulsatile growth hormone release while preserving the body's somatostatin feedback regulation. One of the most commonly prescribed GH peptides, often combined with Ipamorelin for synergistic effects.
CJC-1295 + Ipamorelin
The most commonly prescribed peptide combination in anti-aging and regenerative medicine. Pairs the GHRH analogue CJC-1295 (Mod GRF 1-29) with the selective ghrelin-mimetic Ipamorelin for synergistic, pulsatile growth hormone release. Exploits two complementary signaling pathways — cAMP (GHRH) and calcium/PLC (ghrelin receptor) — to amplify GH pulses while maintaining minimal side effects.